Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database ; volume:24 ; number:1 ; day:22 ; month:4 ; year:2023 ; pages:1-12 ; date:12.2023
BMC nephrology ; 24, Heft 1 (22.4.2023), 1-12, 12.2023
- Creator
-
Chen, Pengwei
Zhu, Jianhong
Xu, Yanchun
Huang, Qiuyan
Su, Jianan
Gao, Ziqing
Feng, Min
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12882-023-03171-9
- URN
-
urn:nbn:de:101:1-2023090209253980921005
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Pengwei
- Zhu, Jianhong
- Xu, Yanchun
- Huang, Qiuyan
- Su, Jianan
- Gao, Ziqing
- Feng, Min
- SpringerLink (Online service)
Other Objects (12)
Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database
Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database
Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database
Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database
The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database
Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database
A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics